JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on CRISPR Therapeutics (CRSP) and maintained an $86 price target.
May 09, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on CRISPR Therapeutics with an $86 price target.
The reiteration of a Market Outperform rating and an $86 price target by JMP Securities suggests a positive outlook on CRISPR Therapeutics' stock. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100